Standard
Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates. / Holt, A.; Blanche, P.; Jensen, A. K. G.; Nouhravesh, N.; Rajan, D.; Jensen, M. H.; El-Sheikh, M.; Schjerning, A. M.; Schou, M.; Torp-Pedersen, C.; Gislason, G. H.; McGettigan, P.; Lamberts, M.
I:
European Heart Journal, Bind 42, Nr. Supplement 1, 2021, s. 3007.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Holt, A
, Blanche, P, Jensen, AKG, Nouhravesh, N, Rajan, D, Jensen, MH
, El-Sheikh, M, Schjerning, AM, Schou, M
, Torp-Pedersen, C, Gislason, GH, McGettigan, P
& Lamberts, M 2021, '
Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates',
European Heart Journal, bind 42, nr. Supplement 1, s. 3007.
https://doi.org/10.1093/eurheartj/ehab724.3007APA
Holt, A.
, Blanche, P., Jensen, A. K. G., Nouhravesh, N., Rajan, D., Jensen, M. H.
, El-Sheikh, M., Schjerning, A. M., Schou, M.
, Torp-Pedersen, C., Gislason, G. H., McGettigan, P.
, & Lamberts, M. (2021).
Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates.
European Heart Journal,
42(Supplement 1), 3007.
https://doi.org/10.1093/eurheartj/ehab724.3007Vancouver
Holt A
, Blanche P, Jensen AKG, Nouhravesh N, Rajan D, Jensen MH o.a.
Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates.
European Heart Journal. 2021;42(Supplement 1):3007.
https://doi.org/10.1093/eurheartj/ehab724.3007Author
Holt, A. ; Blanche, P. ; Jensen, A. K. G. ; Nouhravesh, N. ; Rajan, D. ; Jensen, M. H. ; El-Sheikh, M. ; Schjerning, A. M. ; Schou, M. ; Torp-Pedersen, C. ; Gislason, G. H. ; McGettigan, P. ; Lamberts, M. / Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates. I: European Heart Journal. 2021 ; Bind 42, Nr. Supplement 1. s. 3007.
Bibtex
@article{fda0744d11ca4ae9844dbc8ef3ba4bc1,
title = "Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates",
author = "A. Holt and P. Blanche and Jensen, {A. K. G.} and N. Nouhravesh and D. Rajan and Jensen, {M. H.} and M. El-Sheikh and Schjerning, {A. M.} and M. Schou and C. Torp-Pedersen and Gislason, {G. H.} and P. McGettigan and M. Lamberts",
year = "2021",
doi = "10.1093/eurheartj/ehab724.3007",
language = "English",
volume = "42",
pages = "3007",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "Supplement 1",
}
RIS
TY - ABST
T1 - Usage and risk with phosphodiesterase type 5 inhibitors in male patients with chronic ischemic heart disease on oral organic nitrates
AU - Holt, A.
AU - Blanche, P.
AU - Jensen, A. K. G.
AU - Nouhravesh, N.
AU - Rajan, D.
AU - Jensen, M. H.
AU - El-Sheikh, M.
AU - Schjerning, A. M.
AU - Schou, M.
AU - Torp-Pedersen, C.
AU - Gislason, G. H.
AU - McGettigan, P.
AU - Lamberts, M.
PY - 2021
Y1 - 2021
U2 - 10.1093/eurheartj/ehab724.3007
DO - 10.1093/eurheartj/ehab724.3007
M3 - Conference abstract in journal
VL - 42
SP - 3007
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - Supplement 1
ER -
